Voyager Therapeutics (VYGR) Operating Leases (2019 - 2025)
Historic Operating Leases for Voyager Therapeutics (VYGR) over the last 7 years, with Q3 2025 value amounting to $30.5 million.
- Voyager Therapeutics' Operating Leases fell 2045.45% to $30.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.5 million, marking a year-over-year decrease of 2045.45%. This contributed to the annual value of $36.5 million for FY2024, which is 11351.94% up from last year.
- Per Voyager Therapeutics' latest filing, its Operating Leases stood at $30.5 million for Q3 2025, which was down 2045.45% from $32.6 million recorded in Q2 2025.
- Voyager Therapeutics' Operating Leases' 5-year high stood at $42.1 million during Q1 2021, with a 5-year trough of $17.1 million in Q4 2023.
- Its 5-year average for Operating Leases is $31.0 million, with a median of $34.6 million in 2025.
- Per our database at Business Quant, Voyager Therapeutics' Operating Leases tumbled by 4745.45% in 2022 and then skyrocketed by 11512.73% in 2024.
- Over the past 5 years, Voyager Therapeutics' Operating Leases (Quarter) stood at $38.6 million in 2021, then tumbled by 47.44% to $20.3 million in 2022, then fell by 15.77% to $17.1 million in 2023, then surged by 113.52% to $36.5 million in 2024, then dropped by 16.38% to $30.5 million in 2025.
- Its Operating Leases stands at $30.5 million for Q3 2025, versus $32.6 million for Q2 2025 and $34.6 million for Q1 2025.